graft-versus-host disease

[Frontiers in Immunology] The authors summarize current evidence from in vitro studies, animal models, and their clinical experience, to support stromal cell therapy in multiple clinical indications.

[Journal of Clinical Immunology] Researchers studied transplant outcomes in severe combined immunodeficiency (SCID) infants according to donor type, specifically TCRαβ/CD19-depleted haploidentical family donor transplant, and conditioning, through retrospective cohort analysis of 52 consecutive infants with SCID transplanted between 2013 and 2020.

[Stem Cell Reviews and Reports] The authors describe the effects of various immune cells on intestinal stem cells (ISCs), as well as the mechanisms underlying these effects and also highlight the remarkable role of ISCs in intestinal pathogenesis.

[Bone Marrow Transplantation] In 145 adult recipients developing chronic graft-versus-host disease (cGVHD) after matched sibling or umbilical cord blood donor hematopoietic cell transplantation from 2010 to 2018, two-year cumulative incidence of flares after cGVHD diagnosis was estimated at 60%, with median time-to-first flare of 188 days.

[Bone Marrow Transplantation] Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3 internal tandem duplication mutant transfected Ba/F3 leukemia in mice.

[Molecular Therapy] Investigators treated three children suffering from severe, therapy-refractory GvHD with polyclonally expanded regulatory T cells generated from the original stem cell donor.